RESUMO
The 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), held in Fort Lauderdale, FL, USA, included topics covering new therapeutic developments in the field of eye and vision research. This conference report highlights selected presentations on the development of FOV-2304 (Fovea Pharmaceuticals SA) for the potential treatment of diabetic macular edema; PHA-666859 (Pfizer Inc) for diabetic retinopathy; GTx-878 (GTx Inc) and FCFD-4514S (Genentech Inc) for age-related macular degeneration; SYL-040012 (Sylentis Sau) for ocular hypertension associated with open-angle glaucoma; PEG-PLA-TNP-470 (Harvard Medical School) for ocular neovascularization; recombinant galectin-3 (Senju Pharmaceutical Co Ltd) for corneal injury; and CellBead Neuro (CellMed Inc) for neurological trauma and neurodegeneration.
Assuntos
Oftalmopatias/tratamento farmacológico , Transtornos da Visão/tratamento farmacológico , Animais , Lesões Encefálicas/complicações , Lesões Encefálicas/terapia , Avaliação Pré-Clínica de Medicamentos , Drogas em Investigação/farmacologia , Oftalmopatias/complicações , Oftalmopatias/imunologia , Humanos , Degeneração Neural/complicações , Degeneração Neural/terapia , Transplante de Células-Tronco/métodos , Transtornos da Visão/complicações , Transtornos da Visão/imunologiaRESUMO
The 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), held in Fort Lauderdale, FL, USA, included topics covering new therapeutic developments in the field of eye and vision research. This conference report highlights selected presentations on the development of OT-440 (Othera Pharmaceuticals Inc) for the potential treatment of glaucoma, an extended-release implant of brimonidine (pSivida Corp) for ocular hypertension, AR-12286 (Aerie Pharmaceuticals Inc) for ocular hypertension or glaucoma, AC-8 (Calmune Corp/RiboVax Biotechnologies SA) for ocular diseases following HSV infection, and fidarestat (Sanwa Kagaku Kenkyusho Co Ltd) and the recombinant proteins NOV and NOVCter (INSERM/University Rene Descartes) for corneal neovascularization.